Literature DB >> 19332695

Cancer risk among patients with multiple sclerosis and their parents.

S Bahmanyar1, S M Montgomery, J Hillert, A Ekbom, T Olsson.   

Abstract

BACKGROUND: We investigated cancer risk among patients with multiple sclerosis (MS) and whether variation by age at MS diagnosis helps to elucidate mechanisms underlying the previously reported reduced cancer risk. We also studied cancer risk among parents to ascertain if MS susceptibility genes may confer protection against cancer in relatives.
METHODS: Cox proportional hazards regression, adjusted for age, sex, area, and socioeconomic index, estimated cancer risk among 20,276 patients with MS and 203,951 individuals without MS, using Swedish general population register data. Similar analyses were conducted among 11,284 fathers and 12,006 mothers of patients with MS, compared with 123,158 fathers and 129,409 mothers of controls.
RESULTS: With an average of 35 years of follow-up, there was a decreased overall cancer risk among patients with MS (hazard ratio = 0.91, 0.87-0.95). Increased risks were observed for brain tumors (1.44, 1.21-1.72) and urinary organ cancer (1.27, 1.05-1.53). Parents of patients with MS did not have a notably increased or decreased overall cancer risk.
CONCLUSIONS: The reduction in cancer risk in patients with multiple sclerosis (MS) may result from behavioral change, treatment, or we speculate that some immunologic characteristics of MS disease activity improve antitumor surveillance. The lack of association among parents indicates that a simple inherited characteristic is unlikely to explain the reduced cancer risk among patients with MS. MS is associated with increased risk for some cancers, such as of urinary organs and brain tumors (although surveillance bias may be responsible).

Entities:  

Mesh:

Year:  2009        PMID: 19332695     DOI: 10.1212/01.wnl.0000345366.10455.62

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  42 in total

1.  Racial differences in chronic immune stimulatory conditions and risk of non-Hodgkin's lymphoma in veterans from the United States.

Authors:  Jill Koshiol; Tram Kim Lam; Gloria Gridley; David Check; Linda Morris Brown; Ola Landgren
Journal:  J Clin Oncol       Date:  2010-12-20       Impact factor: 44.544

Review 2.  Inverse cancer comorbidity: a serendipitous opportunity to gain insight into CNS disorders.

Authors:  Rafael Tabarés-Seisdedos; John L Rubenstein
Journal:  Nat Rev Neurosci       Date:  2013-04       Impact factor: 34.870

3.  Association of Demyelinating and Inflammatory Bowel Diseases: A Case Series and Overview of the Literature.

Authors:  Murat Mert Atmaca; Güneş Altiokka Uzun; Erkingül Shugaiv; Murat Kürtüncü; Mefküre Eraksoy
Journal:  Noro Psikiyatr Ars       Date:  2015-07-07       Impact factor: 1.339

Review 4.  Mortality in patients with multiple sclerosis.

Authors:  Antonio Scalfari; Volker Knappertz; Gary Cutter; Douglas S Goodin; Raymond Ashton; George C Ebers
Journal:  Neurology       Date:  2013-07-09       Impact factor: 9.910

5.  Comorbidities at multiple sclerosis diagnosis.

Authors:  Agnès Fromont; Christine Binquet; Fabien Rollot; Romain Despalins; Alain Weill; Laurence Clerc; Claire Bonithon-Kopp; Thibault Moreau
Journal:  J Neurol       Date:  2013-08-02       Impact factor: 4.849

6.  Cancer and multiple sclerosis in the era of disease-modifying treatments.

Authors:  Christine Lebrun; Patrick Vermersch; David Brassat; Gilles Defer; Lucien Rumbach; Pierre Clavelou; Marc Debouverie; Jérôme de Seze; Sandrine Wiertlevsky; Olivier Heinzlef; Ayman Tourbah; Agnes Fromont; Marc Frenay
Journal:  J Neurol       Date:  2011-02-04       Impact factor: 4.849

7.  Genetic characterization of gliomas arising in patients with multiple sclerosis.

Authors:  Adam Khalil; Hilary Serracino; Denise M Damek; Douglas Ney; Kevin O Lillehei; B K Kleinschmidt-DeMasters
Journal:  J Neurooncol       Date:  2012-05-01       Impact factor: 4.130

8.  XVI European Charcot Foundation lecture: nutrition and environment: can MS be prevented?

Authors:  Kelly Claire Simon; Kassandra L Munger; Alberto Ascherio
Journal:  J Neurol Sci       Date:  2011-10-04       Impact factor: 3.181

Review 9.  Cancer Risk in Patients with Multiple Sclerosis: Potential Impact of Disease-Modifying Drugs.

Authors:  Christine Lebrun; Fanny Rocher
Journal:  CNS Drugs       Date:  2018-10       Impact factor: 5.749

10.  Matrix Metalloproteinase-9 (MMP9)-A Mediating Enzyme in Cardiovascular Disease, Cancer, and Neuropsychiatric Disorders.

Authors:  Janusz K Rybakowski
Journal:  Cardiovasc Psychiatry Neurol       Date:  2009-08-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.